Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
Abstract
Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.
- Inventors:
-
- Benicia, CA
- Berkeley, CA
- Issue Date:
- Research Org.:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 909426
- Patent Number(s):
- 7223726
- Application Number:
- 10/342,965
- Assignee:
- The Regents of the University of California (Oakland, CA)
- Patent Classifications (CPCs):
-
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
- DOE Contract Number:
- AC03-76SF00098
- Resource Type:
- Patent
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES
Citation Formats
Oda, Michael N, and Forte, Trudy M. Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same. United States: N. p., 2007.
Web.
Oda, Michael N, & Forte, Trudy M. Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same. United States.
Oda, Michael N, and Forte, Trudy M. Tue .
"Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same". United States. https://www.osti.gov/servlets/purl/909426.
@article{osti_909426,
title = {Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same},
author = {Oda, Michael N and Forte, Trudy M},
abstractNote = {Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2007},
month = {5}
}
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Hydrolysis of platelet-activating factor by human serum paraoxonase
journal, February 2001
- Rodrigo, Lourdes; Mackness, Bharti; Durrington, Paul N.
- Biochemical Journal, Vol. 354, Issue 1
Characterization of human apolipoprotein A-I expressed in Escherichia coli
journal, January 1997
- Bergeron, Jean; Frank, Philippe G.; Emmanuel, Florence
- Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, Vol. 1344, Issue 2
Dietary Fat Modulates Serum Paraoxonase 1 Activity in Rats
journal, October 2000
- Kudchodkar, Bhalchandra J.; Lacko, Andras G.; Dory, Ladislav
- The Journal of Nutrition, Vol. 130, Issue 10
The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano
journal, January 1997
- Bruckert, Eric; von Eckardstein, Arnold; Funke, Harald
- Atherosclerosis, Vol. 128, Issue 1
Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein
journal, December 1997
- Graham, Annette; Hassall, David G.; Rafique, Samina
- Atherosclerosis, Vol. 135, Issue 2
Human Serum Paraoxonase
journal, September 1998
- Mackness, Bharti; Durrington, Paul N.; Mackness, Michael I.
- General Pharmacology: The Vascular System, Vol. 31, Issue 3
Serum Paraoxonase Activity and the Extent of Lipid Peroxidation Are not Affected by Increased Levels of Human Apolipoprotein A-I: Studies in Transgenic Mice
journal, January 2002
- Rosenblat, Mira; Grunfeld, Orit; Hayek, Tony
- Clinical Chemistry and Laboratory Medicine, Vol. 40, Issue 1
High-density lipoprotein composition and paraoxonase activity in Type I diabetes
journal, November 2001
- Valabhji, Jonathan; McCOLL, Avril J.; Schachter, Michael
- Clinical Science, Vol. 101, Issue 6
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
journal, April 1998
- Aviram, M.; Rosenblat, M.; Bisgaier, C. L.
- Journal of Clinical Investigation, Vol. 101, Issue 8
Serum Paraoxonase After Myocardial Infarction
journal, February 1999
- Ayub, Aamir; Mackness, Michael I.; Arrol, Sharon
- Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 19, Issue 2
Recombinant apolipoproteins for the treatment of vascular diseases
journal, January 1999
- Sirtori, Cesare R.; Calabresi, Laura; Franceschini, Guido
- Atherosclerosis, Vol. 142, Issue 1
Paraoxonase 1 Overexpression in Mice and Its Effect on High-Density Lipoproteins
journal, January 2002
- Oda, Michael N.; Bielicki, John K.; Ho, Tamara T.
- Biochemical and Biophysical Research Communications, Vol. 290, Issue 3
Apolipoprotein A-I Milano and Apolipoprotein A-I Paris Exhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I †
journal, February 2002
- Bielicki, John K.; Oda, Michael N.
- Biochemistry, Vol. 41, Issue 6
Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activity †
journal, February 2001
- Oda, Michael N.; Bielicki, John K.; Berger, Trish
- Biochemistry, Vol. 40, Issue 6
Subjects With ApoA-I(Lys 107 →0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)
journal, May 1997
- Tilly-Kiesi, Marju; Lichtenstein, Alice H.; Ordovas, Jose M.
- Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 17, Issue 5
Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
journal, July 1998
- James, Richard W.; Blatter Garin, Marie-Claude; Calabresi, Laura
- Atherosclerosis, Vol. 139, Issue 1